Investment Thesis
BioXcel Therapeutics faces existential financial distress with negative $105.5M stockholders' equity, indicating technical insolvency. Revenue has collapsed 71.7% to just $206K while the company burns $11.8M in annual operating cash with only $17.2M cash remaining. The company cannot service its $100.3M debt burden or meet near-term obligations with a 0.62x current ratio.
Strengths
- Retained $17.2M in cash providing minimal near-term runway
- No capital expenditure preserving liquidity
- Diluted EPS improved 75.6% YoY (though still deeply negative)
Risks
- Negative stockholders' equity of -$105.5M represents technical insolvency
- Revenue collapsed 71.7% YoY to critically low $206K level
- Liquidity crisis with 0.62x current ratio unable to cover short-term obligations
- Operating cash burn of $11.8M annually against only $17.2M cash (~1.5 years runway)
- Debt burden of $100.3M unsustainable against $34M total assets
- Negative interest coverage ratio (-2.8x) indicates inability to service debt
Key Metrics to Watch
- Cash balance depletion rate and months of runway remaining
- Revenue trends and stabilization signals
- Restructuring announcements or capital raise activity
- Debt covenant compliance and refinancing needs
Financial Metrics
Revenue
206.0K
Net Income
-12.7M
EPS (Diluted)
$-0.54
Free Cash Flow
-11.8M
Total Assets
34.0M
Cash
17.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,962.6%
Net Margin
-6,160.7%
ROE
N/A
ROA
-37.3%
FCF Margin
-5,732.5%
Balance Sheet & Liquidity
Current Ratio
0.62x
Quick Ratio
0.61x
Debt/Equity
N/A
Debt/Assets
410.2%
Interest Coverage
-2.77x
Long-term Debt
100.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:28:37.263629 |
Data as of: 2026-03-31 |
Powered by Claude AI